Theravance Biopharma, Inc. Foreign Currency Transaction Gain (Loss), before Tax
Theravance Biopharma, Inc. (TBPH) reported Foreign Currency Transaction Gain (Loss), before Tax of -$100.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-03-23
- Theravance Biopharma, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2024-03-31 was -$100.00K, a 200.00% decline year-over-year.
- Theravance Biopharma, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2023-12-31 was $100.00K, a 95.83% decline year-over-year.
- Theravance Biopharma, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2023-09-30 was $0.00.
- Theravance Biopharma, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2023-06-30 was $0.00.
- Theravance Biopharma, Inc. foreign currency transaction gain (loss), before tax for fiscal 2025 was -$100.00K.
- Theravance Biopharma, Inc. foreign currency transaction gain (loss), before tax for fiscal 2024 was -$100.00K, a 200.00% decline from fiscal 2023.
- Theravance Biopharma, Inc. foreign currency transaction gain (loss), before tax for fiscal 2023 was $100.00K, a 88.89% decline from fiscal 2022.
- Theravance Biopharma, Inc. foreign currency transaction gain (loss), before tax for fiscal 2022 was $900.00K, a 0.00% change from fiscal 2021.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | -$100.00K 10-K · filed 2026-03-23 | ||||
| 2024-12-31 | -$100.00K 10-K · filed 2026-03-23 | ||||
| 2024-03-31 | -$100.00K 10-Q · filed 2024-05-15 | $0.00 derived: sum of 2 quarters · filed 2025-03-07 | $0.00 derived: sum of 3 quarters · filed 2025-03-07 | $0.00 derived: sum of 4 quarters · filed 2025-03-07 | |
| 2023-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $100.00K derived: sum of 2 quarters · filed 2025-03-07 | $100.00K derived: sum of 3 quarters · filed 2025-03-07 | $100.00K 10-K · filed 2025-03-07 | $60.00K 10-K · filed 2024-03-01 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $2.50M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | $2.50M derived: sum of 3 quarters · filed 2024-05-15 | $2.10M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2023-03-31 | $100.00K 10-Q · filed 2024-05-15 | $2.50M derived: sum of 2 quarters · filed 2024-05-15 | $2.10M derived: sum of 3 quarters · filed 2024-05-15 | $1.40M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $2.00M derived: sum of 2 quarters · filed 2024-03-01 | $1.30M derived: sum of 3 quarters · filed 2024-03-01 | $900.00K 10-K · filed 2024-03-01 | |
| 2022-09-30 | -$400.00K 10-Q · filed 2023-11-09 | -$1.10M derived: sum of 2 quarters · filed 2023-11-09 | -$1.50M 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | -$700.00K 10-Q · filed 2023-08-09 | -$1.10M 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | -$400.00K 10-Q · filed 2023-05-10 | ||||
| 2021-12-31 | $900.00K 10-K · filed 2023-03-01 | -$900.00K 10-K · filed 2022-02-28 | |||
| 2020-12-31 | $300.00K 10-K · filed 2023-03-01 | -$300.00K 10-K · filed 2022-02-28 | |||
| 2019-12-31 | $200.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |